



# m-PIMA™ HIV-1/2 VL POINT OF CARE HIV VIRAL LOAD IN LESS THAN 70 MINUTES, NOT MONTHS.

Scale-up of viral load testing is a global priority, but countries face numerous challenges.

- Limited laboratory infrastructure
- Shortage of skilled clinical and laboratory staff
- Weak specimen transport systems
- Inefficient systems for result feedback
- Lost samples, lost results, and patients lost to follow up



# m-PIMA™ HIV-1/2 VL

**ACTIONABLE RESULTS IN LESS THAN 70 MINUTES WHILE THE PATIENT IS STILL PRESENT**

- Instead of sending samples to a lab, bring the test system to the patient
- ART failure can be detected early
- ART switching decisions can be made the same day
- ART adherence problems can be addressed the same day
- Reduced sample transport costs
- Lost samples, lost results, and patients lost to follow up potentially reduced

**WHO recommends that all patients on ART receive a viral load test at 6 months and 12 months, and annually thereafter if the patient is stable on ART<sup>1</sup>, but very few patients receive that level of care.**

**44%** 90-90-90: 90% of patients on ART to be virally suppressed by 2020, but only 44% actually are.<sup>2</sup>

**50%** Approximately 50% of the viral load testing need in low to middle income countries is unmet.<sup>2</sup>

**30 million** By 2021 low to middle income countries will need an estimated 30 million viral load tests.<sup>3</sup>

**VIRAL LOAD MONITORING HAS THE POTENTIAL TO SUPPORT THE REALIZATION OF THE 90-90-90 GOALS.**

## SPECIFICATIONS

- Lower limit of quantitation: 800 cp/mL for HIV-1 and HIV-2 RNA (below the WHO cut-off value of <1000 cp/mL)
- Method: Reverse Transcription and Real Time PCR with multiplexing capabilities
- Time to results: less than 70 minutes
- Sample volume: 50 µL
- Sample type: venous EDTA plasma
- Storage conditions: 4-30°C
- Connectivity: enabled

**CURRENT ALTERNATIVES**  
**WEEKS**  
**OR MONTHS**

**VS**

**POINT OF CARE**  
**LESS THAN**  
**70 MINUTES**



## ORDER INFO

PART	ORDER NUMBER	QTY/BOX
m-PIMA™ Analyser	27030R001	1
m-PIMA™ Complete (Analyser, PowerDrum, Printer w/Paper, Connectivity Pack)	27030R002	1
m-PIMA™ HIV-1/2 VL Cartridge (IVD)	27015-W50	50
PowerDrum	27040R004	1
USB Printer	27040R007	1

NOT CLEARED/APPROVED OR FOR SALE IN USA.

1. WHO: What's new in treatment monitoring: viral load and CD4 testing. July 2017  
2. Ending AIDS: progress towards the 90-90-90 targets 2017  
3. Lauren & Bijl, LMIC Forecast Demand for Diagnostic Tests 2016-2021, Avenir Health

© 2018 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. 120004377 08/2018

